{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-172425","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.679902+00:00","generated_at":"2026-06-25T02:23:10.957724+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amylyx receives first global approval: Health Canada approves ALBRIOZA for ALS","bullets":["Health Canada approved ALBRIOZA (AMX0035) with conditions for ALS; first marketing approval worldwide.","Approval based on Phase 2 CENTAUR trial showing 2.32-point higher ALSFRS-R score vs placebo over 24 weeks.","Condition requires data from ongoing Phase 3 PHOENIX trial; topline results expected in 2024.","ALBRIOZA expected to be commercially available in Canada within six weeks.","FDA PDUFA date set for Sept 29, 2022; EMA application under review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-172425","json":"https://secwatch.observer/filing/0001193125-22-172425.json","markdown":"https://secwatch.observer/filing/0001193125-22-172425.md","text":"https://secwatch.observer/filing/0001193125-22-172425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312522172425/0001193125-22-172425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312522172425/d358853d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:23:10.957724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}